Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9083280 | 1.00 | PPM1B (0.43) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL14393314 | 1.00 | PPM1B (0.43) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL14400889 | 1.00 | PPM1B (0.43) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL9083292 | 1.00 | PPM1B (0.43) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL4521342 | 1.00 | PPM1B (0.43) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4415435 | 0.98 | PPM1B (0.42) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4415434 | 0.98 | PPM1B (0.42) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4415429 | 0.98 | PPM1B (0.42) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL11111768 | 0.92 | PPM1B (0.46) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL14614764 | 0.92 | PPM1B (0.46) | PPM1BPTPN1PPP1CCMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-116134035-B | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-1495022-B1 | DIAZABICYCLO ALKANE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2009-07-08 | — | — | EP | disclosed |
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-7202238-B2 | Diazabicyclo alkane derivatives with NK1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-04-10 | — | — | US | disclosed |
| US-20060019959-A1 | Novel quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. TSUKUBA RESEARCH INSTITUTE (JP) | 2006-01-26 | — | — | US | disclosed |
| WO-2005095339-A1 | DICYANOPYRROLIDINES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1557418-A1 | NOVEL QUINOXALINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20050119267-A1 | Diazabicyclo alkane derivatives with nk1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-06-02 | — | — | US | disclosed |
| US-5543521-A | ENDOTHELIN ANTAGONISTS; TREATING CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | IMMUNOPHARMACEUTICS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| US-3948933-A | CNS DEPRESSANTS, TRANQUILIZERS, ANXIOLYTIC | GRUPPO LEPETIT S.P.A. (IT) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | PPM1B 1639/4885PTPN1 2229/4885PPP1CC 822/4885 |
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | PPM1B 2525/4885PTPN1 1725/4885PPP1CC 4239/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | PPM1B 1639/4885PTPN1 2229/4885PPP1CC 822/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | PPM1B 914/4885PTPN1 975/4885PPP1CC 2769/4885 |
| US-20050119267-A1 | Diazabicyclo alkane derivatives with nk1 antagonistic activity | TAC3, TACR2, OPRK1 | PPM1B 3348/4885PTPN1 1598/4885PPP1CC 4119/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | PPM1B 1639/4885PTPN1 2229/4885PPP1CC 822/4885 |
| US-20060019959-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB11 | PPM1B 2393/4885PTPN1 1345/4885PPP1CC 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.